MO936KIDNEY RE-TRANSPLANTATION: NOT TOO OLD FOR A SECOND CHANCE

Abstract Background and Aims A growing number of end-stage renal disease patients waiting for a kidney transplant (KT) are older than 50 years old. Consequently, many recipients will be in need dialysis or re-transplantation at an age. For young patients, offers advantage over but the elderly these benefits not well established. selected recipients, with rigorous cardiovascular neoplastic evaluation, immunosenescence might actually provide graft outcomes. Our aim was to compare major clinical outcomes between younger 60 old re-transplantation, first second KT Method We performed retrospective, longitudinal study, that included all submitted January 2008 December 2019, excluding more 2 grafts multi-organ transplant. defined two groups according recipient’s age re-transplant, years-old, compared such as biopsy proven acute rejection, death-censored survival patients’ survival. Afterwards, we years, same KT. Follow-up time 1st June 2020 functioning failure (including death graft). Results 109 KT, 13 (12%) 60-years-old (group 1), mean 62.85 ± 2.9 96 (88%) 2), 40.4 10.6 years. Group 1 were male (100% vs 59.4%; p=0.004) had higher body mass index (25±2.8 22.5±3.6 kg/m2, p=0.016). Recipients from group 1, waited less their (37.7±21.8 64.8±58.8 months; p=0.003), donors (59.5±13.5 45.9±11.5 old; p<0.001), significantly expanded-criteria (76.9% 26%; p<0.001). HLA mismatch PRA (%) similar both groups. Regarding there no events 21 (22%) (p<0.05). Death censored (logrank test p=0.124) year 5 1: 91.7%, 82.5% versus 2: 90.1%, 85.2% p=0.944). found difference mortality follow up p=0.0124). Focusing on differences N=13) 2, N=390) 60-year-old, males one, other recipient donor demographic characteristics, (38±22 47±25 months, p=0.17). As expected, (25 ±29% 3.7±11%, p=0.018) matching. At follow-up, post-transplant 47±39.68 63 ±39.9 months (p=0.144). There regarding rejection episodes (0% 3.1%; p=0.521) 93.4%, 86.3% p=0.983). Conclusion In carefully advanced should contraindication re-transplantation. Immunosenescense lead lower rates used restrictions. our comparable counterparts graft.